Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res

Retrieve available abstracts of 346 articles:
HTML format



Single Articles


    March 2024
  1. HAMILTON AM, Walens A, Van Alsten SC, Olsson LT, et al
    BIRC5 expression by race, age and clinical factors in breast cancer patients.
    Breast Cancer Res. 2024;26:50.
    PubMed     Abstract available


  2. MCCLELLAN JC, Li JL, Gao G, Huo D, et al
    Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status.
    Breast Cancer Res. 2024;26:51.
    PubMed     Abstract available


  3. LEE J, Lee G, Park HS, Jeong BK, et al
    Factors associated with engraftment success of patient-derived xenografts of breast cancer.
    Breast Cancer Res. 2024;26:49.
    PubMed     Abstract available


  4. HU R, Cao Y, Wang Y, Zhao T, et al
    TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via beta1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
    Breast Cancer Res. 2024;26:48.
    PubMed     Abstract available


  5. GONZALEZ-FERNANDEZ L, Romero-Morales C, Martinez-Pascual B, Rio-Gonzalez A, et al
    Breast cancer survivors suffering from lymphedema: What really do affect to corporeality/body image? A qualitative study.
    Breast Cancer Res. 2024;26:47.
    PubMed     Abstract available


  6. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
    Breast Cancer Res. 2024;26:46.
    PubMed    


  7. PEREIRA A, Garmendia ML, Leiva V, Corvalan C, et al
    Breast composition during and after puberty: the Chilean Growth and Obesity Cohort Study.
    Breast Cancer Res. 2024;26:45.
    PubMed     Abstract available


  8. JACOBS LM, Helder LS, Albers KI, Kranendonk J, et al
    The role of surgical tissue injury and intraoperative sympathetic activation in postoperative immunosuppression after breast-conserving surgery versus mastectomy: a prospective observational study.
    Breast Cancer Res. 2024;26:42.
    PubMed     Abstract available


  9. CONNER SJ, Guarin JR, Le TT, Fatherree JP, et al
    Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential.
    Breast Cancer Res. 2024;26:43.
    PubMed     Abstract available


  10. BAEZ-NAVARRO X, van den Ende NS, Nguyen AH, Sinke R, et al
    HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Breast Cancer Res. 2024;26:41.
    PubMed     Abstract available


  11. LI J, Liang Y, Zhou S, Chen J, et al
    UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
    Breast Cancer Res. 2024;26:44.
    PubMed     Abstract available


  12. ZHAO L, Xing Y, Liu C, Ma S, et al
    Detection of HER2 expression using (99m)Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.
    Breast Cancer Res. 2024;26:40.
    PubMed     Abstract available


  13. CASTRESANA-AGUIRRE M, Johansson A, Matikas A, Foukakis T, et al
    Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
    Breast Cancer Res. 2024;26:38.
    PubMed     Abstract available


  14. HAN Y, Otegbeye EE, Stoll C, Hardi A, et al
    How does weight gain since the age of 18 years affect breast cancer risk in later life? A meta-analysis.
    Breast Cancer Res. 2024;26:39.
    PubMed     Abstract available


  15. JIANG X, Wang Y, Guo L, Wang Y, et al
    The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
    Breast Cancer Res. 2024;26:37.
    PubMed     Abstract available


  16. RODON J, Demanse D, Rugo HS, Burris HA, et al
    A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
    Breast Cancer Res. 2024;26:36.
    PubMed     Abstract available


  17. SMOOTS SG, Schreiber AR, Jackson MM, Bagby SM, et al
    Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
    Breast Cancer Res. 2024;26:35.
    PubMed     Abstract available


    February 2024
  18. SONG T, Zhang H, Zhao Q, Hu Z, et al
    Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance.
    Breast Cancer Res. 2024;26:33.
    PubMed     Abstract available


  19. EDWARDS CM, Kane JF, Smith JA, Grant DM, et al
    PTHrP intracrine actions divergently influence breast cancer growth through p27 and LIFR.
    Breast Cancer Res. 2024;26:34.
    PubMed     Abstract available


  20. SHATSKY RA, Batra-Sharma H, Helsten T, Schwab RB, et al
    A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
    Breast Cancer Res. 2024;26:32.
    PubMed     Abstract available


  21. JUNG M, Song SG, Cho SI, Shin S, et al
    Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
    Breast Cancer Res. 2024;26:31.
    PubMed     Abstract available


  22. HEESCH A, Florea A, Maurer J, Habib P, et al
    The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [(177)Lu]Lu-PSMA-I&T for triple-negative breast cancer.
    Breast Cancer Res. 2024;26:30.
    PubMed     Abstract available


  23. DEROUANE F, Desgres M, Moroni C, Ambroise J, et al
    Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.
    Breast Cancer Res. 2024;26:29.
    PubMed     Abstract available


  24. SCHEFFGES C, Devy J, Giustiniani J, Francois S, et al
    Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
    Breast Cancer Res. 2024;26:28.
    PubMed     Abstract available


  25. LI JK, Jin ZY, Xu YJ, Fu NQ, et al
    Contrast-enhanced ultrasound to predict malignant upgrading of atypical ductal hyperplasia.
    Breast Cancer Res. 2024;26:27.
    PubMed     Abstract available


  26. WANG M, Du S, Gao S, Zhao R, et al
    MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
    Breast Cancer Res. 2024;26:26.
    PubMed     Abstract available


  27. SANTERAMO R, Damiani C, Wei J, Montana G, et al
    Are better AI algorithms for breast cancer detection also better at predicting risk? A paired case-control study.
    Breast Cancer Res. 2024;26:25.
    PubMed     Abstract available


  28. RONNLUND C, Sifakis EG, Schagerholm C, Yang Q, et al
    Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:24.
    PubMed     Abstract available


  29. LUNDBERG P, Abrahamsson A, Kihlberg J, Tellman J, et al
    Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women.
    Breast Cancer Res. 2024;26:22.
    PubMed     Abstract available


  30. QIAN J, Ma Y, Tahaney WM, Moyer CL, et al
    The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
    Breast Cancer Res. 2024;26:23.
    PubMed     Abstract available


  31. LEE J, Nishikawa RM
    Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover.
    Breast Cancer Res. 2024;26:21.
    PubMed     Abstract available


    January 2024
  32. LYNCE F, Stevens LE, Li Z, Brock JE, et al
    TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
    Breast Cancer Res. 2024;26:20.
    PubMed     Abstract available


  33. NIE J, Dang S, Zhu R, Lu T, et al
    ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
    Breast Cancer Res. 2024;26:19.
    PubMed     Abstract available


  34. HAN X, Guo Y, Ye H, Chen Z, et al
    Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
    Breast Cancer Res. 2024;26:18.
    PubMed     Abstract available


  35. SHARMA A, Weitz P, Wang Y, Liu B, et al
    Development and prognostic validation of a three-level NHG-like deep learning-based model for histological grading of breast cancer.
    Breast Cancer Res. 2024;26:17.
    PubMed     Abstract available


  36. SUN X, Reiner AS, Tran AP, Watt GP, et al
    A genome-wide association study of contralateral breast cancer in the Women's Environmental Cancer and Radiation Epidemiology Study.
    Breast Cancer Res. 2024;26:16.
    PubMed     Abstract available


  37. KANG E, Jung JJ, Lim C, Kim HK, et al
    Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study.
    Breast Cancer Res. 2024;26:14.
    PubMed     Abstract available


  38. NABILA S, Choi JY, Abe SK, Islam MR, et al
    Differential patterns of reproductive and lifestyle risk factors for breast cancer according to birth cohorts among women in China, Japan and Korea.
    Breast Cancer Res. 2024;26:15.
    PubMed     Abstract available


  39. FISHER TB, Saini G, Rekha TS, Krishnamurthy J, et al
    Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
    Breast Cancer Res. 2024;26:12.
    PubMed     Abstract available


  40. PARK J, Chang ES, Kim JY, Chelakkot C, et al
    c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2024;26:13.
    PubMed     Abstract available


  41. BAGGER MM, Sjolund J, Kim J, Kohler KT, et al
    Evidence of steady-state fibroblast subtypes in the normal human breast as cells-of-origin for perturbed-state fibroblasts in breast cancer.
    Breast Cancer Res. 2024;26:11.
    PubMed     Abstract available


  42. PENG ZM, Han XJ, Wang T, Li JJ, et al
    PFKP deubiquitination and stabilization by USP5 activate aerobic glycolysis to promote triple-negative breast cancer progression.
    Breast Cancer Res. 2024;26:10.
    PubMed     Abstract available


  43. DING N, Pang J, Liu X, He X, et al
    Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial.
    Breast Cancer Res. 2024;26:9.
    PubMed     Abstract available


  44. PADAMSEE TJ, Bijou C, Swinehart-Hord P, Hils M, et al
    Risk-management decision-making data from a community-based sample of racially diverse women at high risk of breast cancer: rationale, methods, and sample characteristics of the Daughter Sister Mother Project survey.
    Breast Cancer Res. 2024;26:8.
    PubMed     Abstract available


  45. DELL'AQUILA K, Vadlamani A, Maldjian T, Fineberg S, et al
    Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city population.
    Breast Cancer Res. 2024;26:7.
    PubMed     Abstract available


  46. BLOCK I, Mateu-Regue A, Do TTN, Miceikaite I, et al
    Male with an apparently normal phenotype carrying a BRCA1 exon 20 duplication in trans to a BRCA1 frameshift variant.
    Breast Cancer Res. 2024;26:6.
    PubMed     Abstract available


  47. HACHEY SJ, Hatch CJ, Gaebler D, Mocherla A, et al
    Targeting tumor-stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model.
    Breast Cancer Res. 2024;26:5.
    PubMed     Abstract available


  48. LOPEZ-VELAZCO JI, Manzano S, Otano M, Elorriaga K, et al
    A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
    Breast Cancer Res. 2024;26:3.
    PubMed     Abstract available


  49. BRAUNE EB, Geist F, Tang X, Kalari K, et al
    Identification of a Notch transcriptomic signature for breast cancer.
    Breast Cancer Res. 2024;26:4.
    PubMed     Abstract available


  50. TAO J, Xue C, Cao M, Ye J, et al
    Protein disulfide isomerase family member 4 promotes triple-negative breast cancer tumorigenesis and radiotherapy resistance through JNK pathway.
    Breast Cancer Res. 2024;26:1.
    PubMed     Abstract available


  51. ZIRPOLI GR, Pfeiffer RM, Bertrand KA, Huo D, et al
    Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black women.
    Breast Cancer Res. 2024;26:2.
    PubMed     Abstract available


    December 2023
  52. GUAN Y, Shen J, Lu J, Fuemmeler BF, et al
    Association between allostatic load and breast cancer risk: a cohort study.
    Breast Cancer Res. 2023;25:155.
    PubMed     Abstract available


  53. CHENG HF, Tsai YF, Liu CY, Hsu CY, et al
    Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
    Breast Cancer Res. 2023;25:152.
    PubMed     Abstract available


  54. DAYAN D, Lukac S, Rack B, Ebner F, et al
    Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.
    Breast Cancer Res. 2023;25:153.
    PubMed     Abstract available


  55. SEO J, Koh J, Lee DW, Kim J, et al
    HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
    Breast Cancer Res. 2023;25:154.
    PubMed     Abstract available


  56. OLIVOS N, Banta JE, Spencer-Hwang R, Ansong D, et al
    Mosquito control exposures and breast cancer risk: analysis of 1071 cases and 2096 controls from the Ghana Breast Health Study.
    Breast Cancer Res. 2023;25:150.
    PubMed     Abstract available


  57. HU P, Zhou P, Sun T, Liu D, et al
    Therapeutic protein PAK restrains the progression of triple negative breast cancer through degrading SREBP-1 mRNA.
    Breast Cancer Res. 2023;25:151.
    PubMed     Abstract available


  58. HUNG SK, Yang HJ, Lee MS, Liu DW, et al
    Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study.
    Breast Cancer Res. 2023;25:149.
    PubMed     Abstract available


    November 2023
  59. TAN Z, Deme P, Boyapati K, Claes BSR, et al
    Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer.
    Breast Cancer Res. 2023;25:148.
    PubMed     Abstract available


  60. ATAKPA EC, Buist DSM, Aiello Bowles EJ, Cuzick J, et al
    Development and evaluation of a method to assess breast cancer risk using a longitudinal history of mammographic density: a cohort study.
    Breast Cancer Res. 2023;25:147.
    PubMed     Abstract available


  61. GOKER M, Denys H, Hendrix A, De Wever O, et al
    Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer.
    Breast Cancer Res. 2023;25:146.
    PubMed     Abstract available


  62. VERSCHOOR N, Smid M, Jager A, Sleijfer S, et al
    Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer.
    Breast Cancer Res. 2023;25:145.
    PubMed     Abstract available


  63. SHARMA D, Hager CG, Shang L, Tran L, et al
    The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling.
    Breast Cancer Res. 2023;25:144.
    PubMed     Abstract available


  64. FRANCO-VALLS H, Tusquets-Uxo E, Sala L, Val M, et al
    Formation of an invasion-permissive matrix requires TGFbeta/SNAIL1-regulated alternative splicing of fibronectin.
    Breast Cancer Res. 2023;25:143.
    PubMed     Abstract available


  65. ASWOLINSKIY W, Munari E, Horlings HM, Mulder L, et al
    PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.
    Breast Cancer Res. 2023;25:142.
    PubMed     Abstract available


  66. CAMPONE M, Bidard FC, Neven P, Wang L, et al
    AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.
    Breast Cancer Res. 2023;25:141.
    PubMed     Abstract available


  67. BRACKENBURY WJ, Palmieri C
    Blocking channels to metastasis: targeting sodium transport in breast cancer.
    Breast Cancer Res. 2023;25:140.
    PubMed     Abstract available


  68. NIELSEN K, Sode M, Jensen MB, Berg T, et al
    High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients.
    Breast Cancer Res. 2023;25:139.
    PubMed     Abstract available


  69. KAZEROUNI AS, Peterson LM, Jenkins I, Novakova-Jiresova A, et al
    Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
    Breast Cancer Res. 2023;25:138.
    PubMed     Abstract available


  70. WEBSTER JL, Goldstein ND, Rowland JP, Tuite CM, et al
    A catchment and location-allocation analysis of mammography access in Delaware, US: implications for disparities in geographic access to breast cancer screening.
    Breast Cancer Res. 2023;25:137.
    PubMed     Abstract available


  71. HO PJ, Khng AJ, Tan BK, Lim GH, et al
    Alterations to DNA methylation patterns induced by chemotherapy treatment are associated with negative impacts on the olfactory pathway.
    Breast Cancer Res. 2023;25:136.
    PubMed     Abstract available


  72. CHOI JE, Lee JS, Jin MS, Nikas IP, et al
    The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer.
    Breast Cancer Res. 2023;25:134.
    PubMed     Abstract available


  73. MOKBEL K, Alamoodi M
    Exploring the interface zone in breast cancer: implications for surgical strategies and beyond.
    Breast Cancer Res. 2023;25:135.
    PubMed    


  74. FLAQUE MCD, Galigniana NM, Beguelin W, Vicario R, et al
    Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.
    Breast Cancer Res. 2023;25:133.
    PubMed    


  75. YU Y, Ren W, He Z, Chen Y, et al
    Machine learning radiomics of magnetic resonance imaging predicts recurrence-free survival after surgery and correlation of LncRNAs in patients with breast cancer: a multicenter cohort study.
    Breast Cancer Res. 2023;25:132.
    PubMed     Abstract available


    October 2023
  76. BOUAMAR H, Broome LE, Lathrop KI, Jatoi I, et al
    mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers.
    Breast Cancer Res. 2023;25:131.
    PubMed     Abstract available


  77. BUSUND M, Ursin G, Lund E, Wilsgaard T, et al
    Trajectories of body mass index in adulthood and risk of subtypes of postmenopausal breast cancer.
    Breast Cancer Res. 2023;25:130.
    PubMed     Abstract available


  78. ZHANG H, Gao M, Zhao W, Yu L, et al
    The chromatin architectural regulator SND1 mediates metastasis in triple-negative breast cancer by promoting CDH1 gene methylation.
    Breast Cancer Res. 2023;25:129.
    PubMed     Abstract available


  79. YE Z, Nguyen TL, Dite GS, MacInnis RJ, et al
    Causal relationships between breast cancer risk factors based on mammographic features.
    Breast Cancer Res. 2023;25:127.
    PubMed     Abstract available


  80. JUNG J, Kim NH, Kwon M, Park J, et al
    The inhibitory effect of Gremlin-2 on adipogenesis suppresses breast cancer cell growth and metastasis.
    Breast Cancer Res. 2023;25:128.
    PubMed     Abstract available


  81. ZHU S, Zhang M, Liu X, Luo Q, et al
    Single-cell transcriptomics provide insight into metastasis-related subsets of breast cancer.
    Breast Cancer Res. 2023;25:126.
    PubMed     Abstract available


  82. RAMESSUR A, Ambasager B, Valle Aramburu I, Peakman F, et al
    Circulating neutrophils from patients with early breast cancer have distinct subtype-dependent phenotypes.
    Breast Cancer Res. 2023;25:125.
    PubMed     Abstract available


  83. LIU C, Lu C, Yixi L, Hong J, et al
    Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR.
    Breast Cancer Res. 2023;25:124.
    PubMed     Abstract available


  84. SIGURJONSDOTTIR G, De Marchi T, Ehinger A, Hartman J, et al
    Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
    Breast Cancer Res. 2023;25:123.
    PubMed     Abstract available



  85. Symposium Mammographicum 2023.
    Breast Cancer Res. 2023;25.
    PubMed    


  86. GETZ KR, Jeon MS, Luo C, Luo J, et al
    Lipidome of mammographic breast density in premenopausal women.
    Breast Cancer Res. 2023;25:121.
    PubMed     Abstract available


  87. BROEKER CD, Ortiz MMO, Murillo MS, Andrechek ER, et al
    Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity.
    Breast Cancer Res. 2023;25:120.
    PubMed     Abstract available


  88. JONAS K, Prinz F, Ferracin M, Krajina K, et al
    MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib.
    Breast Cancer Res. 2023;25:119.
    PubMed     Abstract available


  89. ZHOU L, Wu J, Ruan M, Xiao Y, et al
    The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition.
    Breast Cancer Res. 2023;25:115.
    PubMed     Abstract available


  90. STEENBRUGGEN TG, Wolf DM, Campbell MJ, Sanders J, et al
    B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    Breast Cancer Res. 2023;25:117.
    PubMed     Abstract available


  91. OLINDER J, Johnson K, Akesson A, Fornvik D, et al
    Impact of breast density on diagnostic accuracy in digital breast tomosynthesis versus digital mammography: results from a European screening trial.
    Breast Cancer Res. 2023;25:116.
    PubMed     Abstract available


  92. WATSON J, Wang T, Ho KL, Feng Y, et al
    Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
    Breast Cancer Res. 2023;25:114.
    PubMed     Abstract available


  93. QI X, Shi Q, Xuhong J, Zhang Y, et al
    Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
    Breast Cancer Res. 2023;25:113.
    PubMed     Abstract available


  94. DUNLOP HM, Williams LJ, Hall PS, Barber M, et al
    Evaluation of the association of area-level socioeconomic deprivation and breast cancer recurrence by oestrogen receptor subtypes in Scotland.
    Breast Cancer Res. 2023;25:106.
    PubMed     Abstract available


  95. ZOLLNER L, Torres D, Briceno I, Gilbert M, et al
    Native American ancestry and breast cancer risk in Colombian and Mexican women: ruling out potential confounding through ancestry-informative markers.
    Breast Cancer Res. 2023;25:111.
    PubMed     Abstract available


  96. GERRATANA L, Davis AA, Velimirovic M, Clifton K, et al
    Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
    Breast Cancer Res. 2023;25:112.
    PubMed     Abstract available


    September 2023
  97. LUNDGREN C, Tutzauer J, Church SE, Stal O, et al
    Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.
    Breast Cancer Res. 2023;25:110.
    PubMed     Abstract available


  98. LUO D, Liang Y, Wang Y, Ye F, et al
    Long non-coding RNA MIDEAS-AS1 inhibits growth and metastasis of triple-negative breast cancer via transcriptionally activating NCALD.
    Breast Cancer Res. 2023;25:109.
    PubMed     Abstract available


  99. ZAHL PH
    Re: Non-progressive breast carcinomas detected at mammography screening: a population study-a model test or a novel test of cancer regression?
    Breast Cancer Res. 2023;25:108.
    PubMed    


  100. JAN R, Huang M, Lewis-Wambi J
    Retraction Note: Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Breast Cancer Res. 2023;25:107.
    PubMed    


  101. SUNDEN M, Norgren S, Lundqvist R, Andersson A, et al
    Receptor conversion and survival in breast cancer liver metastases.
    Breast Cancer Res. 2023;25:105.
    PubMed     Abstract available


  102. BLYTH RRR, Birts CN, Beers SA
    The role of three-dimensional in vitro models in modelling the inflammatory microenvironment associated with obesity in breast cancer.
    Breast Cancer Res. 2023;25:104.
    PubMed     Abstract available


    August 2023
  103. NEVEN P, Fasching PA, Chia S, Jerusalem G, et al
    Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
    Breast Cancer Res. 2023;25:103.
    PubMed     Abstract available


  104. HAPACH LA, Wang W, Schwager SC, Pokhriyal D, et al
    Phenotypically sorted highly and weakly migratory triple negative breast cancer cells exhibit migratory and metastatic commensalism.
    Breast Cancer Res. 2023;25:102.
    PubMed     Abstract available


  105. LOFLING LL, Stoer NC, Andreassen BK, Ursin G, et al
    Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study.
    Breast Cancer Res. 2023;25:101.
    PubMed     Abstract available


  106. YANG W, Xu M, Xu S, Guan Q, et al
    Single-cell RNA reveals a tumorigenic microenvironment in the interface zone of human breast tumors.
    Breast Cancer Res. 2023;25:100.
    PubMed     Abstract available


  107. CASTILLO-CASTREJON M, Sankofi BM, Murguia SJ, Udeme AA, et al
    FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.
    Breast Cancer Res. 2023;25:99.
    PubMed     Abstract available


  108. LIU S, Chen W, Hu H, Zhang T, et al
    Correction: Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1.
    Breast Cancer Res. 2023;25:98.
    PubMed    


  109. ABUBAKAR M, Klein A, Fan S, Lawrence S, et al
    Host, reproductive, and lifestyle factors in relation to quantitative histologic metrics of the normal breast.
    Breast Cancer Res. 2023;25:97.
    PubMed     Abstract available


  110. ZHOU F, Yang G, Xue L, Liu Y, et al
    SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.
    Breast Cancer Res. 2023;25:96.
    PubMed     Abstract available


  111. DEROUEN MC, Yang J, Li Y, Franke AA, et al
    Circulating 27-hydroxycholesterol, lipids, and steroid hormones in breast cancer risk: a nested case-control study of the Multiethnic Cohort Study.
    Breast Cancer Res. 2023;25:95.
    PubMed     Abstract available


  112. MUOIO MG, Pellegrino M, Rapicavoli V, Talia M, et al
    Publisher Correction: RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer.
    Breast Cancer Res. 2023;25:94.
    PubMed    


  113. MIDDHA P, Wang X, Behrens S, Bolla MK, et al
    A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.
    Breast Cancer Res. 2023;25:93.
    PubMed     Abstract available


  114. HABEL LA, Alexeeff SE, Achacoso N, Arasu VA, et al
    Examination of fully automated mammographic density measures using LIBRA and breast cancer risk in a cohort of 21,000 non-Hispanic white women.
    Breast Cancer Res. 2023;25:92.
    PubMed     Abstract available


  115. MARTINEZ-ILLESCAS NG, Leal S, Gonzalez P, Grana-Castro O, et al
    miR-203 drives breast cancer cell differentiation.
    Breast Cancer Res. 2023;25:91.
    PubMed     Abstract available


    July 2023
  116. DAI H, Xu W, Wang L, Li X, et al
    Loss of SPRY2 contributes to cancer-associated fibroblasts activation and promotes breast cancer development.
    Breast Cancer Res. 2023;25:90.
    PubMed     Abstract available


  117. MOHL A, Behrens S, Flasskamp F, Obi N, et al
    The impact of cardiovascular disease on all-cause and cancer mortality: results from a 16-year follow-up of a German breast cancer case-control study.
    Breast Cancer Res. 2023;25:89.
    PubMed     Abstract available


  118. ZHENG C, Xu X, Wu M, Xue L, et al
    Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance.
    Breast Cancer Res. 2023;25:88.
    PubMed     Abstract available


  119. ADAM R, Dell'Aquila K, Hodges L, Maldjian T, et al
    Deep learning applications to breast cancer detection by magnetic resonance imaging: a literature review.
    Breast Cancer Res. 2023;25:87.
    PubMed     Abstract available


  120. CHUANGCHOT N, Jamjuntra P, Yangngam S, Luangwattananun P, et al
    Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways.
    Breast Cancer Res. 2023;25:86.
    PubMed     Abstract available


  121. MUOIO MG, Pellegrino M, Rapicavoli V, Talia M, et al
    RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer.
    Breast Cancer Res. 2023;25:84.
    PubMed     Abstract available


  122. XIA W, Chen W, Ni C, Meng X, et al
    Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway.
    Breast Cancer Res. 2023;25:85.
    PubMed     Abstract available


  123. SMOTHERMAN C, Sprague B, Datta S, Braithwaite D, et al
    Association of air pollution with postmenopausal breast cancer risk in UK Biobank.
    Breast Cancer Res. 2023;25:83.
    PubMed     Abstract available


  124. GERMAN R, Marino N, Hemmerich C, Podicheti R, et al
    Exploring breast tissue microbial composition and the association with breast cancer risk factors.
    Breast Cancer Res. 2023;25:82.
    PubMed     Abstract available


  125. ZHANG J, McAndrew NP, Wang X, Du Y, et al
    Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
    Breast Cancer Res. 2023;25:81.
    PubMed     Abstract available


  126. HEGGLAND T, Vatten LJ, Opdahl S, Weedon-Fekjaer H, et al
    Non-progressive breast carcinomas detected at mammography screening: a population study.
    Breast Cancer Res. 2023;25:80.
    PubMed     Abstract available


    June 2023
  127. PARK AY, Han MR, Seo BK, Ju HY, et al
    MRI-based breast cancer radiogenomics using RNA profiling: association with subtypes in a single-center prospective study.
    Breast Cancer Res. 2023;25:79.
    PubMed     Abstract available


  128. ALVES DA COSTA F, Cardoso Borges F, Ramos A, Mayer A, et al
    Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice.
    Breast Cancer Res. 2023;25:78.
    PubMed     Abstract available


  129. TENG X, Zhang J, Zhang X, Fan X, et al
    Noninvasive imaging signatures of HER2 and HR using ADC in invasive breast cancer: repeatability, reproducibility, and association with pathological complete response to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:77.
    PubMed     Abstract available


  130. KATZENELLENBOGEN BS, Guillen VS, Katzenellenbogen JA
    Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
    Breast Cancer Res. 2023;25:76.
    PubMed     Abstract available


  131. ZHANG Y, Lv L, Zheng R, Xie R, et al
    Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.
    Breast Cancer Res. 2023;25:75.
    PubMed     Abstract available



  132. Meeting Abstracts from the British Society of Breast Radiology Annual Scientific Meeting 2022.
    Breast Cancer Res. 2023;25.
    PubMed    


  133. KAST K, John EM, Hopper JL, Andrieu N, et al
    Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium.
    Breast Cancer Res. 2023;25:72.
    PubMed     Abstract available


  134. LIEFAARD MC, van der Voort A, van Ramshorst MS, Sanders J, et al
    BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
    Breast Cancer Res. 2023;25:71.
    PubMed     Abstract available


  135. ARYANNEJAD A, Saeedi Moghaddam S, Mashinchi B, Tabary M, et al
    Correction to: National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019.
    Breast Cancer Res. 2023;25:70.
    PubMed    


  136. ANDERSEN LVB, Larsen MJ, Davies H, Degasperi A, et al
    Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness.
    Breast Cancer Res. 2023;25:69.
    PubMed     Abstract available


  137. O'LEARY KA, Bates AM, Jin WJ, Burkel BM, et al
    Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy.
    Breast Cancer Res. 2023;25:68.
    PubMed     Abstract available


  138. SCHMID P, Cortes J, Joaquim A, Janez NM, et al
    XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
    Breast Cancer Res. 2023;25:67.
    PubMed     Abstract available


  139. YOUNG KL, Olshan AF, Lunetta K, Graff M, et al
    Influence of alcohol consumption and alcohol metabolism variants on breast cancer risk among Black women: results from the AMBER consortium.
    Breast Cancer Res. 2023;25:66.
    PubMed     Abstract available


  140. ILLIPSE M, Czene K, Hall P, Humphreys K, et al
    Studying the association between longitudinal mammographic density measurements and breast cancer risk: a joint modelling approach.
    Breast Cancer Res. 2023;25:64.
    PubMed     Abstract available


  141. FERRONI G, Sabeti S, Abdus-Shakur T, Scalise L, et al
    Noninvasive prediction of axillary lymph node breast cancer metastasis using morphometric analysis of nodal tumor microvessels in a contrast-free ultrasound approach.
    Breast Cancer Res. 2023;25:65.
    PubMed     Abstract available


  142. YANG C, Liu J, Zhao S, Shang Q, et al
    Infiltrating myeloid cell diversity determines oncological characteristics and clinical outcomes in breast cancer.
    Breast Cancer Res. 2023;25:63.
    PubMed     Abstract available


  143. LIU S, Xie SM, Liu W, Gagea M, et al
    Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
    Breast Cancer Res. 2023;25:62.
    PubMed     Abstract available


    May 2023
  144. XU JB, Cao J, Xia J, Zhu Y, et al
    Breast metastatic tumors in lung can be substituted by lung-derived malignant cells transformed by alternative splicing H19 lncRNA.
    Breast Cancer Res. 2023;25:59.
    PubMed     Abstract available


  145. COELINGH BENNINK HJT, Schultz IJ, Schmidt M, Jordan VC, et al
    Progesterone from ovulatory menstrual cycles is an important cause of breast cancer.
    Breast Cancer Res. 2023;25:60.
    PubMed     Abstract available


  146. LANG M, Liang P, Shen H, Li H, et al
    Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study.
    Breast Cancer Res. 2023;25:61.
    PubMed     Abstract available


  147. MIYASHITA M, Bell JSK, Wenric S, Karaesmen E, et al
    Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
    Breast Cancer Res. 2023;25:58.
    PubMed     Abstract available


  148. TANG X, Thompson KJ, Kalari KR, Sinnwell JP, et al
    Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.
    Breast Cancer Res. 2023;25:57.
    PubMed     Abstract available


  149. HOFFMANN E, Gerwing M, Krahling T, Hansen U, et al
    Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.
    Breast Cancer Res. 2023;25:56.
    PubMed     Abstract available


  150. QI M, Yi X, Yue B, Huang M, et al
    S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy.
    Breast Cancer Res. 2023;25:55.
    PubMed     Abstract available


  151. PETERSON JR, Cole JA, Pfeiffer JR, Norris GH, et al
    Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.
    Breast Cancer Res. 2023;25:54.
    PubMed     Abstract available


  152. SMID M, Schmidt MK, Prager-van der Smissen WJC, Ruigrok-Ritstier K, et al
    Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
    Breast Cancer Res. 2023;25:53.
    PubMed     Abstract available


  153. VAN DER NOORD VE, van der Stel W, Louwerens G, Verhoeven D, et al
    Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
    Breast Cancer Res. 2023;25:51.
    PubMed     Abstract available


  154. RAMIN C, Veiga LHS, Vo JB, Curtis RE, et al
    Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort.
    Breast Cancer Res. 2023;25:50.
    PubMed     Abstract available


    April 2023
  155. ARYANNEJAD A, Saeedi Moghaddam S, Mashinchi B, Tabary M, et al
    National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019.
    Breast Cancer Res. 2023;25:47.
    PubMed     Abstract available


  156. ZHANG J, Qin Z, So TH, Chang TY, et al
    Acupuncture for chemotherapy-associated insomnia in breast cancer patients: an assessor-participant blinded, randomized, sham-controlled trial.
    Breast Cancer Res. 2023;25:49.
    PubMed     Abstract available


  157. RAGU ME, Lim JMC, Ng PS, Yip CH, et al
    TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects.
    Breast Cancer Res. 2023;25:48.
    PubMed     Abstract available


  158. LEE S, Toft NJ, Axelsen TV, Espejo MS, et al
    Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer.
    Breast Cancer Res. 2023;25:46.
    PubMed     Abstract available


  159. COHEN SY, Stoll CR, Anandarajah A, Doering M, et al
    Modifiable risk factors in women at high risk of breast cancer: a systematic review.
    Breast Cancer Res. 2023;25:45.
    PubMed     Abstract available


  160. MANI C, Acharya G, Saamarthy K, Ochola D, et al
    Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.
    Breast Cancer Res. 2023;25:44.
    PubMed     Abstract available


  161. LIU H, Yan R, Xiao Z, Huang X, et al
    Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Breast Cancer Res. 2023;25:43.
    PubMed     Abstract available


  162. LE CORNET C, Jung AY, Johnson TS, Behrens S, et al
    Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort.
    Breast Cancer Res. 2023;25:42.
    PubMed     Abstract available


  163. ZHANG X, Gunda A, Kranenbarg EM, Liefers GJ, et al
    Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial.
    Breast Cancer Res. 2023;25:40.
    PubMed     Abstract available


  164. MURAKAMI-NISHIMAGI Y, Sugimoto K, Kobayashi M, Tachibana K, et al
    Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor beta.
    Breast Cancer Res. 2023;25:41.
    PubMed     Abstract available


  165. BLISS JM, Tovey H, Evans A, Holcombe C, et al
    Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
    Breast Cancer Res. 2023;25:39.
    PubMed     Abstract available


  166. ZHANG F, Zheng Z, Wang L, Zeng W, et al
    PKC-zeta mediated reduction of the extracellular vesicles-associated TGF-beta1 overcomes radiotherapy resistance in breast cancer.
    Breast Cancer Res. 2023;25:38.
    PubMed     Abstract available


  167. JANEVA S, Krabbe E, Parris TZ, Nasic S, et al
    Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer.
    Breast Cancer Res. 2023;25:36.
    PubMed     Abstract available


  168. DURAN CL, Karagiannis GS, Chen X, Sharma VP, et al
    Cooperative NF-kappaB and Notch1 signaling promotes macrophage-mediated MenaINV expression in breast cancer.
    Breast Cancer Res. 2023;25:37.
    PubMed     Abstract available


    March 2023
  169. MASALA G, Bendinelli B, Caini S, Duroni G, et al
    Lifetime changes in body fatness and breast density in postmenopausal women: the FEDRA study.
    Breast Cancer Res. 2023;25:35.
    PubMed     Abstract available


  170. HU XE, Yang P, Chen S, Wei G, et al
    Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low.
    Breast Cancer Res. 2023;25:34.
    PubMed     Abstract available


  171. YAGHJYAN L, Heng YJ, Baker GM, Rosner BA, et al
    Associations of alcohol consumption with breast tissue composition.
    Breast Cancer Res. 2023;25:33.
    PubMed     Abstract available


  172. WIMBERGER P, Blohmer JU, Krabisch P, Link T, et al
    The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
    Breast Cancer Res. 2023;25:32.
    PubMed     Abstract available


  173. ROLLAND AL, Porro B, Kab S, Ribet C, et al
    Impact of breast cancer care pathways and related symptoms on the return-to-work process: results from a population-based French cohort study (CONSTANCES).
    Breast Cancer Res. 2023;25:30.
    PubMed     Abstract available


  174. WANG W, Rana PS, Markovic V, Sossey-Alaoui K, et al
    The WAVE3/beta-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
    Breast Cancer Res. 2023;25:31.
    PubMed     Abstract available


  175. GUNNARSDOTTIR FB, Bendahl PO, Johansson A, Benfeitas R, et al
    Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.
    Breast Cancer Res. 2023;25:29.
    PubMed     Abstract available


  176. HANAMURA T, Kitano S, Kagamu H, Yamashita M, et al
    Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
    Breast Cancer Res. 2023;25:28.
    PubMed    


  177. TUNALI G, Yanik H, Ozturk SC, Demirkol-Canli S, et al
    A positive feedback loop driven by fibronectin and IL-1beta sustains the inflammatory microenvironment in breast cancer.
    Breast Cancer Res. 2023;25:27.
    PubMed     Abstract available


  178. PECAR G, Liu S, Hooda J, Atkinson JM, et al
    RET signaling in breast cancer therapeutic resistance and metastasis.
    Breast Cancer Res. 2023;25:26.
    PubMed     Abstract available


  179. CHAUDHARY S, Appadurai MI, Maurya SK, Nallasamy P, et al
    MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR.
    Breast Cancer Res. 2023;25:25.
    PubMed     Abstract available


  180. HATHAWAY CA, Rice MS, Collins LC, Chen D, et al
    Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers.
    Breast Cancer Res. 2023;25:24.
    PubMed     Abstract available


    February 2023
  181. CHEN ZH, Tian Y, Zhou GL, Yue HR, et al
    CMTM7 inhibits breast cancer progression by regulating Wnt/beta-catenin signaling.
    Breast Cancer Res. 2023;25:22.
    PubMed     Abstract available


  182. SAEKI S, Kumegawa K, Takahashi Y, Yang L, et al
    Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin.
    Breast Cancer Res. 2023;25:21.
    PubMed     Abstract available


  183. LEE ES, Kim Y, Shin HC, Hwang KT, et al
    Diagnostic accuracy of a three-protein signature in women with suspicious breast lesions: a multicenter prospective trial.
    Breast Cancer Res. 2023;25:20.
    PubMed     Abstract available


  184. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
    Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.
    Breast Cancer Res. 2023;25:18.
    PubMed     Abstract available


  185. OUYANG D, Hong T, Fu M, Li Y, et al
    METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
    Breast Cancer Res. 2023;25:19.
    PubMed     Abstract available


  186. CHOWDHURY A, Pharoah PD, Rueda OM
    Evaluation and comparison of different breast cancer prognosis scores based on gene expression data.
    Breast Cancer Res. 2023;25:17.
    PubMed     Abstract available


  187. PAVLOV MV, Bavrina AP, Plekhanov VI, Golubyatnikov GY, et al
    Correction: Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:16.
    PubMed    


  188. STEVENS VL, Carter BD, Jacobs EJ, McCullough ML, et al
    Correction: A prospective case-cohort analysis of plasma metabolites and breast cancer risk.
    Breast Cancer Res. 2023;25:15.
    PubMed    


    January 2023
  189. HANAMURA T, Kitano S, Kagamu H, Yamashita M, et al
    Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
    Breast Cancer Res. 2023;25:13.
    PubMed     Abstract available


  190. AYENI OA, Jofe M, Mapanga W, Chen WC, et al
    Correction: Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study.
    Breast Cancer Res. 2023;25:14.
    PubMed    


  191. PAVLOV MV, Bavrina AP, Plekhanov VI, Golubyatnikov GY, et al
    Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.
    Breast Cancer Res. 2023;25:12.
    PubMed     Abstract available


  192. LIEN HC, Hsu CL, Lu YS, Chen TW, et al
    Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma.
    Breast Cancer Res. 2023;25:11.
    PubMed     Abstract available


  193. LIU Z, Choksi S, Kwon HJ, Jiao D, et al
    Tumor necroptosis-mediated shedding of cell surface proteins promotes metastasis of breast cancer by suppressing anti-tumor immunity.
    Breast Cancer Res. 2023;25:10.
    PubMed     Abstract available


  194. SCHONBERG MA, Wolfson EA, Eliassen AH, Bertrand KA, et al
    A model for predicting both breast cancer risk and non-breast cancer death among women > 55 years old.
    Breast Cancer Res. 2023;25:8.
    PubMed     Abstract available


  195. WANG Y, Liu F, Sun L, Jia Y, et al
    Association between human blood metabolome and the risk of breast cancer.
    Breast Cancer Res. 2023;25:9.
    PubMed     Abstract available


  196. AYENI OA, Joffe M, Mapanga W, Chen WC, et al
    Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study.
    Breast Cancer Res. 2023;25:7.
    PubMed     Abstract available


  197. TODHUNTER ME, Miyano M, Carlson EG, Hinz S, et al
    Sustained postconfluent culture of human mammary epithelial cells enriches for luminal and c-Kit+ subtypes.
    Breast Cancer Res. 2023;25:6.
    PubMed     Abstract available


  198. STEVENS VL, Carter BD, Jacobs EJ, McCullough ML, et al
    A prospective case-cohort analysis of plasma metabolites and breast cancer risk.
    Breast Cancer Res. 2023;25:5.
    PubMed     Abstract available


  199. CAO Z, Liu R, Li Y, Luo X, et al
    MTX-PEG-modified CG/DMMA polymeric micelles for targeted delivery of doxorubicin to induce synergistic autophagic death against triple-negative breast cancer.
    Breast Cancer Res. 2023;25:3.
    PubMed     Abstract available


  200. KIM CG, Kim MH, Kim JH, Kim SG, et al
    On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
    Breast Cancer Res. 2023;25:4.
    PubMed     Abstract available


  201. DE HAAS SL, Slamon DJ, Martin M, Press MF, et al
    Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
    Breast Cancer Res. 2023;25:2.
    PubMed     Abstract available


  202. CHEN S, Paul MR, Sterner CJ, Belka GK, et al
    PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.
    Breast Cancer Res. 2023;25:1.
    PubMed     Abstract available


    December 2022
  203. ANANDARAJAH A, Chen Y, Colditz GA, Hardi A, et al
    Studies of parenchymal texture added to mammographic breast density and risk of breast cancer: a systematic review of the methods used in the literature.
    Breast Cancer Res. 2022;24:101.
    PubMed     Abstract available


  204. SHAH JS, Milevskiy MJG, Petrova V, Au AYM, et al
    Towards resolution of the intron retention paradox in breast cancer.
    Breast Cancer Res. 2022;24:100.
    PubMed     Abstract available


  205. LUO J, Zou H, Guo Y, Tong T, et al
    SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.
    Breast Cancer Res. 2022;24:99.
    PubMed     Abstract available


  206. YADAV N, Sunder R, Desai S, Dharavath B, et al
    Progesterone modulates the DSCAM-AS1/miR-130a/ESR1 axis to suppress cell invasion and migration in breast cancer.
    Breast Cancer Res. 2022;24:97.
    PubMed     Abstract available


  207. JOE NS, Godet I, Milki N, Ain NUI, et al
    Mebendazole prevents distant organ metastases in part by decreasing ITGbeta4 expression and cancer stemness.
    Breast Cancer Res. 2022;24:98.
    PubMed     Abstract available


  208. LEE ARGOV EJ, Rodriguez CB, Agovino M, Wei Y, et al
    Breast cancer worry, uncertainty, and perceived risk following breast density notification in a longitudinal mammography screening cohort.
    Breast Cancer Res. 2022;24:95.
    PubMed     Abstract available


  209. KIM S, Tran TXM, Song H, Park B, et al
    Microcalcifications, mammographic breast density, and risk of breast cancer: a cohort study.
    Breast Cancer Res. 2022;24:96.
    PubMed     Abstract available


  210. FERNANDEZ G, Prastawa M, Madduri AS, Scott R, et al
    Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years.
    Breast Cancer Res. 2022;24:93.
    PubMed     Abstract available


  211. PAN Y, Yang Y, Huang R, Yang H, et al
    Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors.
    Breast Cancer Res. 2022;24:92.
    PubMed     Abstract available


  212. SIRVEN P, Faucheux L, Grandclaudon M, Michea P, et al
    Definition of a novel breast tumor-specific classifier based on secretome analysis.
    Breast Cancer Res. 2022;24:94.
    PubMed     Abstract available


  213. DORGAN JF, Baer HJ, Bertrand KA, LeBlanc ES, et al
    Childhood adiposity, serum metabolites and breast density in young women.
    Breast Cancer Res. 2022;24:91.
    PubMed     Abstract available


  214. SGROI DC, Treuner K, Zhang Y, Piper T, et al
    Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
    Breast Cancer Res. 2022;24:90.
    PubMed     Abstract available


  215. YAGHJYAN L, Eliassen AH, Colditz G, Rosner B, et al
    Associations of aspirin and other anti-inflammatory medications with breast cancer risk by the status of COX-2 expression.
    Breast Cancer Res. 2022;24:89.
    PubMed     Abstract available


  216. SEMINA SE, Alejo LH, Chopra S, Kansara NS, et al
    Identification of a novel ER-NFkB-driven stem-like cell population associated with relapse of ER+ breast tumors.
    Breast Cancer Res. 2022;24:88.
    PubMed     Abstract available


  217. HASSAINE Y, Jacquet E, Seigneurin A, Delafosse P, et al
    Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?
    Breast Cancer Res. 2022;24:87.
    PubMed     Abstract available


  218. DAVIS LYNN BC, Lord BD, Cora R, Pfeiffer RM, et al
    Associations between quantitative measures of TDLU involution and breast tumor molecular subtypes among breast cancer cases in the Black Women's Health Study: a case-case analysis.
    Breast Cancer Res. 2022;24:86.
    PubMed     Abstract available


    November 2022
  219. GU J, Ternifi R, Sabeti S, Larson NB, et al
    Volumetric imaging and morphometric analysis of breast tumor angiogenesis using a new contrast-free ultrasound technique: a feasibility study.
    Breast Cancer Res. 2022;24:85.
    PubMed     Abstract available


  220. PHILIPPSON C, Larsen S, Simon S, Vandekerkhove C, et al
    Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry.
    Breast Cancer Res. 2022;24:83.
    PubMed     Abstract available


  221. BALLINGER TJ, Thompson WR, Guise TA
    The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health.
    Breast Cancer Res. 2022;24:84.
    PubMed     Abstract available


  222. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:82.
    PubMed    


  223. WU L, Ye W, Liu Y, Chen D, et al
    An integrated deep learning model for the prediction of pathological complete response to neoadjuvant chemotherapy with serial ultrasonography in breast cancer patients: a multicentre, retrospective study.
    Breast Cancer Res. 2022;24:81.
    PubMed     Abstract available


  224. BALLOT E, Galland L, Mananet H, Boidot R, et al
    Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    Breast Cancer Res. 2022;24:80.
    PubMed     Abstract available


  225. KOLYVAS EA, Caldas C, Kelly K, Ahmad SS, et al
    Androgen receptor function and targeted therapeutics across breast cancer subtypes.
    Breast Cancer Res. 2022;24:79.
    PubMed     Abstract available


  226. ASAD S, Damicis A, Heng YJ, Kananen K, et al
    Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.
    Breast Cancer Res. 2022;24:78.
    PubMed     Abstract available


  227. PEDERSEN DC, Jensen BW, Tjonneland A, Andersen ZJ, et al
    Birthweight, childhood body size, and timing of puberty and risks of breast cancer by menopausal status and tumor receptor subtypes.
    Breast Cancer Res. 2022;24:77.
    PubMed     Abstract available


  228. SZABOVA L, Gordon MB, Lu L, Pate N, et al
    Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins.
    Breast Cancer Res. 2022;24:75.
    PubMed     Abstract available


  229. CRAGER M, Wijayawardana SR, Gruver AM, Blacklock A, et al
    Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score(R) result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer.
    Breast Cancer Res. 2022;24:74.
    PubMed     Abstract available


    October 2022
  230. HAN SJ, Sung N, Wang J, O'Malley BW, et al
    Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment.
    Breast Cancer Res. 2022;24:73.
    PubMed     Abstract available


  231. KARTHIKEYAN S, Casey PJ, Wang M
    RAB4A GTPase regulates epithelial-to-mesenchymal transition by modulating RAC1 activation.
    Breast Cancer Res. 2022;24:72.
    PubMed     Abstract available


  232. LA VERDE N, Damia G, Garrone O, Santini D, et al
    Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
    Breast Cancer Res. 2022;24:71.
    PubMed     Abstract available


  233. DU T, Pan L, Zheng C, Chen K, et al
    Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
    Breast Cancer Res. 2022;24:70.
    PubMed     Abstract available


  234. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:69.
    PubMed     Abstract available


  235. ZHENG ZY, Elsarraj H, Lei JT, Hong Y, et al
    Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
    Breast Cancer Res. 2022;24:68.
    PubMed     Abstract available


  236. ONAGI H, Horimoto Y, Sakaguchi A, Ikarashi D, et al
    High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs.
    Breast Cancer Res. 2022;24:67.
    PubMed     Abstract available


  237. NOUNU A, Kar SP, Relton CL, Richmond RC, et al
    Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study.
    Breast Cancer Res. 2022;24:66.
    PubMed     Abstract available


  238. LUCHTENBORG AM, Metzger P, Cosenza Contreras M, Oria V, et al
    Kruppel-like factor 7 influences translation and pathways involved in ribosomal biogenesis in breast cancer.
    Breast Cancer Res. 2022;24:65.
    PubMed     Abstract available


    September 2022
  239. ZIOLKOWSKI P, Wozniak M, Mansour A, An Y, et al
    Breast cancer risk in papilloma patients: Osteopontin splice variants indicate prognosis.
    Breast Cancer Res. 2022;24:64.
    PubMed     Abstract available


  240. DENG N, Minoche A, Harvey K, Li M, et al
    Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models.
    Breast Cancer Res. 2022;24:63.
    PubMed     Abstract available


  241. LOPEZ-KNOWLES E, Detre S, Hills M, Schuster EF, et al
    Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
    Breast Cancer Res. 2022;24:61.
    PubMed     Abstract available


  242. LI C, Yoshimura T, Tian M, Wang Y, et al
    Exosomal Wnt7a from a low metastatic subclone promotes lung metastasis of a highly metastatic subclone in the murine 4t1 breast cancer.
    Breast Cancer Res. 2022;24:60.
    PubMed     Abstract available


  243. LOUDIG O, Mitchell MI, Ben-Dov IZ, Liu C, et al
    MiRNA expression deregulation correlates with the Oncotype DX((R)) DCIS score.
    Breast Cancer Res. 2022;24:62.
    PubMed     Abstract available


  244. DUGUE PA, Bodelon C, Chung FF, Brewer HR, et al
    Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies.
    Breast Cancer Res. 2022;24:59.
    PubMed     Abstract available


  245. KOLBERG-LIEDTKE C, Feuerhake F, Garke M, Christgen M, et al
    Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Breast Cancer Res. 2022;24:58.
    PubMed     Abstract available


    August 2022
  246. LIU C, Hu S, Xu X, Zhang Y, et al
    Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment.
    Breast Cancer Res. 2022;24:57.
    PubMed     Abstract available


  247. CLARKE S, Chin SN, Dodds L, George SHL, et al
    Racial disparities in breast cancer preclinical and clinical models.
    Breast Cancer Res. 2022;24:56.
    PubMed     Abstract available


    July 2022
  248. JONES LI, Marshall A, Elangovan P, Geach R, et al
    Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched dataset.
    Breast Cancer Res. 2022;24:55.
    PubMed     Abstract available


  249. LEE S, Osmanbeyoglu HU
    Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.
    Breast Cancer Res. 2022;24:54.
    PubMed     Abstract available


  250. PAPADAKI C, Stratigos M, Markakis G, Spiliotaki M, et al
    Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
    Breast Cancer Res. 2022;24:53.
    PubMed    


  251. HANNA A, Nixon MJ, Estrada MV, Sanchez V, et al
    Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.
    Breast Cancer Res. 2022;24:51.
    PubMed     Abstract available


  252. SALVATI A, Melone V, Sellitto A, Rizzo F, et al
    Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
    Breast Cancer Res. 2022;24:52.
    PubMed     Abstract available


  253. VAN GEELEN CT, Savas P, Teo ZL, Luen SJ, et al
    Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    Breast Cancer Res. 2022;24:50.
    PubMed    


  254. WARD SV, Burton A, Tamimi RM, Pereira A, et al
    The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density.
    Breast Cancer Res. 2022;24:49.
    PubMed     Abstract available


  255. MIR S, Golden BDO, Griess BJ, Vengoji R, et al
    Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction.
    Breast Cancer Res. 2022;24:48.
    PubMed     Abstract available


  256. AL-TWEIGERI T, AlRaouji NN, Tulbah A, Arafah M, et al
    High AUF1 level in stromal fibroblasts promotes carcinogenesis and chemoresistance and predicts unfavorable prognosis among locally advanced breast cancer patients.
    Breast Cancer Res. 2022;24:46.
    PubMed     Abstract available


  257. KEHM RD, Walter EJ, Oskar S, White ML, et al
    Exposure to polycyclic aromatic hydrocarbons during pregnancy and breast tissue composition in adolescent daughters and their mothers: a prospective cohort study.
    Breast Cancer Res. 2022;24:47.
    PubMed     Abstract available


  258. OGONY J, de Bel T, Radisky DC, Kachergus J, et al
    Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence.
    Breast Cancer Res. 2022;24:45.
    PubMed     Abstract available


    June 2022
  259. WAGNER KU
    Know thy cells: commonly used triple-negative human breast cancer cell lines carry mutations in RAS and effectors.
    Breast Cancer Res. 2022;24:44.
    PubMed    


  260. PEDERSEN CA, Cao MD, Fleischer T, Rye MB, et al
    DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
    Breast Cancer Res. 2022;24:43.
    PubMed     Abstract available


  261. WELLBERG EA, Corleto KA, Checkley LA, Jindal S, et al
    Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer.
    Breast Cancer Res. 2022;24:42.
    PubMed     Abstract available


  262. RATZ L, Brambillasca C, Bartke L, Huetzen MA, et al
    Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Breast Cancer Res. 2022;24:41.
    PubMed     Abstract available


  263. CARR D, Zein A, Coulombe J, Jiang T, et al
    Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology.
    Breast Cancer Res. 2022;24:40.
    PubMed     Abstract available


  264. ONG CHC, Lee DY, Lee B, Li H, et al
    Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
    Breast Cancer Res. 2022;24:38.
    PubMed     Abstract available


  265. HARRASSER M, Gohil SH, Lau H, Della Peruta M, et al
    Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Breast Cancer Res. 2022;24:39.
    PubMed     Abstract available


  266. SIEGEL SD, Brooks MM, Lynch SM, Sims-Mourtada J, et al
    Racial disparities in triple negative breast cancer: toward a causal architecture approach.
    Breast Cancer Res. 2022;24:37.
    PubMed     Abstract available


    May 2022
  267. KOEVOETS EW, Schagen SB, de Ruiter MB, Geerlings MI, et al
    Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study).
    Breast Cancer Res. 2022;24:36.
    PubMed     Abstract available


  268. RAGHAVAKAIMAL A, Cristofanilli M, Tang CM, Alpaugh RK, et al
    CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome.
    Breast Cancer Res. 2022;24:35.
    PubMed     Abstract available


  269. RALLI GP, Carter RD, McGowan DR, Cheng WC, et al
    Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism.
    Breast Cancer Res. 2022;24:34.
    PubMed     Abstract available


  270. SWERDLOW AJ, Bruce C, Cooke R, Coulson P, et al
    Infertility and risk of breast cancer in men: a national case-control study in England and Wales.
    Breast Cancer Res. 2022;24:29.
    PubMed     Abstract available


  271. ROUSSEAU B, Murugan S, Palagani A, Sarkar DK, et al
    Beta 2 adrenergic receptor and mu opioid receptor interact to potentiate the aggressiveness of human breast cancer cell by activating the glycogen synthase kinase 3 signaling.
    Breast Cancer Res. 2022;24:33.
    PubMed     Abstract available


  272. ZHENG J, Zhang B
    Biological interpretation of prognostic radiomic score by correlating with tumor heterogeneity and microenvironment.
    Breast Cancer Res. 2022;24:32.
    PubMed    


  273. HO WJ, Law AMK, Masle-Farquhar E, Castillo LE, et al
    Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases.
    Breast Cancer Res. 2022;24:31.
    PubMed     Abstract available


    April 2022
  274. GRINMAN DY, Boras-Granic K, Takyar FM, Dann P, et al
    PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development.
    Breast Cancer Res. 2022;24:30.
    PubMed     Abstract available


  275. MINTZ R, Wang M, Xu S, Colditz GA, et al
    Hormone and receptor activator of NF-kappaB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women.
    Breast Cancer Res. 2022;24:28.
    PubMed     Abstract available


  276. CHEN H, Fan S, Stone J, Thompson DJ, et al
    Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci.
    Breast Cancer Res. 2022;24:27.
    PubMed     Abstract available


  277. LIU Z, Liu J, Ebrahimi B, Pratap UP, et al
    SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Breast Cancer Res. 2022;24:26.
    PubMed     Abstract available


  278. FOO SL, Sachaphibulkij K, Lee CLY, Yap GLR, et al
    Breast cancer metastasis to brain results in recruitment and activation of microglia through annexin-A1/formyl peptide receptor signaling.
    Breast Cancer Res. 2022;24:25.
    PubMed     Abstract available


  279. RENAULT AL, Dowty JG, Steen JA, Li S, et al
    Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
    Breast Cancer Res. 2022;24:24.
    PubMed     Abstract available


  280. HEYNEN GJJE, Lisek K, Vogel R, Wulf-Goldenberg A, et al
    Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
    Breast Cancer Res. 2022;24:23.
    PubMed     Abstract available


    March 2022
  281. WON HS, Ahn J, Kim Y, Kim JS, et al
    Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res. 2022;24:22.
    PubMed     Abstract available


  282. TU CF, Li FA, Li LH, Yang RB, et al
    Quantitative glycoproteomics analysis identifies novel FUT8 targets and signaling networks critical for breast cancer cell invasiveness.
    Breast Cancer Res. 2022;24:21.
    PubMed     Abstract available


  283. WANG X, Xie T, Luo J, Zhou Z, et al
    Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment.
    Breast Cancer Res. 2022;24:20.
    PubMed     Abstract available


  284. SEMINA SE, Pal P, Kansara NS, Huggins RJ, et al
    Selective pressure of endocrine therapy activates the integrated stress response through NFkappaB signaling in a subpopulation of ER positive breast cancer cells.
    Breast Cancer Res. 2022;24:19.
    PubMed     Abstract available


  285. LIU M, Smith R, Liby T, Chiotti K, et al
    INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.
    Breast Cancer Res. 2022;24:18.
    PubMed     Abstract available


  286. WATT AC, Goel S
    Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer.
    Breast Cancer Res. 2022;24:17.
    PubMed     Abstract available


  287. GU J, Ternifi R, Larson NB, Carter JM, et al
    Hybrid high-definition microvessel imaging/shear wave elastography improves breast lesion characterization.
    Breast Cancer Res. 2022;24:16.
    PubMed     Abstract available


    February 2022
  288. SYRIOPOULOU E, Gasparini A, Humphreys K, Andersson TM, et al
    Assessing lead time bias due to mammography screening on estimates of loss in life expectancy.
    Breast Cancer Res. 2022;24:15.
    PubMed     Abstract available


  289. GASTOUNIOTI A, Desai S, Ahluwalia VS, Conant EF, et al
    Artificial intelligence in mammographic phenotyping of breast cancer risk: a narrative review.
    Breast Cancer Res. 2022;24:14.
    PubMed     Abstract available


  290. THOMPSON KN, Ju JA, Ory EC, Pratt SJP, et al
    Microtubule disruption reduces metastasis more effectively than primary tumor growth.
    Breast Cancer Res. 2022;24:13.
    PubMed     Abstract available


  291. SUN L, Ding H, Jia Y, Shi M, et al
    Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Breast Cancer Res. 2022;24:12.
    PubMed     Abstract available


  292. WEI G, Teng M, Rosa M, Wang X, et al
    Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    Breast Cancer Res. 2022;24:11.
    PubMed     Abstract available


    January 2022
  293. REN Q, Khoo WH, Corr AP, Phan TG, et al
    Gene expression predicts dormant metastatic breast cancer cell phenotype.
    Breast Cancer Res. 2022;24:10.
    PubMed     Abstract available


  294. GECZIK AM, Falk RT, Xu X, Ansong D, et al
    Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana Breast Health Study.
    Breast Cancer Res. 2022;24:9.
    PubMed     Abstract available


  295. TANG YH, Rockstroh A, Sokolowski KA, Lynam LR, et al
    Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
    Breast Cancer Res. 2022;24:8.
    PubMed     Abstract available


  296. YIN L, Li Q, Mrdenovic S, Chu GC, et al
    KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway.
    Breast Cancer Res. 2022;24:7.
    PubMed     Abstract available


  297. DESHPANDE RP, Sharma S, Liu Y, Pandey PR, et al
    LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c.
    Breast Cancer Res. 2022;24:6.
    PubMed     Abstract available


  298. PIRIKAHU S, Lund H, Cadby G, Wylie E, et al
    The impact of breast density notification on rescreening rates within a population-based mammographic screening program.
    Breast Cancer Res. 2022;24:5.
    PubMed     Abstract available


  299. HJERKIND KV, Johansson ALV, Trewin CB, Russnes HG, et al
    Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway.
    Breast Cancer Res. 2022;24:4.
    PubMed     Abstract available


  300. YOON L, Corvalan C, Pereira A, Shepherd J, et al
    Sugar-sweetened beverage consumption and breast composition in a longitudinal study of Chilean girls.
    Breast Cancer Res. 2022;24:3.
    PubMed     Abstract available


  301. MENG L, Chang S, Sang Y, Ding P, et al
    Circular RNA circCCDC85A inhibits breast cancer progression via acting as a miR-550a-5p sponge to enhance MOB1A expression.
    Breast Cancer Res. 2022;24:1.
    PubMed     Abstract available


  302. AHEARN TU, Zhang H, Michailidou K, Milne RL, et al
    Common variants in breast cancer risk loci predispose to distinct tumor subtypes.
    Breast Cancer Res. 2022;24:2.
    PubMed     Abstract available


    December 2021
  303. NIWINSKA A, Olszewski WP
    The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.
    Breast Cancer Res. 2021;23:118.
    PubMed     Abstract available


  304. SANDSVEDEN M, Borgquist S, Rosendahl AH, Manjer J, et al
    Low thyroid hormone receptor alpha-2 (THRalpha-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality.
    Breast Cancer Res. 2021;23:117.
    PubMed     Abstract available


  305. CHEUNG AM, Wang D, Liu K, Hope T, et al
    Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes.
    Breast Cancer Res. 2021;23:114.
    PubMed     Abstract available


  306. ZHANG M, Meng M, Liu Y, Qi J, et al
    Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
    Breast Cancer Res. 2021;23:116.
    PubMed     Abstract available


  307. LIU S, Chen W, Hu H, Zhang T, et al
    Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1.
    Breast Cancer Res. 2021;23:115.
    PubMed     Abstract available


  308. YAGHOOBI V, Moutafi M, Aung TN, Pelekanou V, et al
    Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.
    Breast Cancer Res. 2021;23:113.
    PubMed     Abstract available


  309. GAMPENRIEDER SP, Rinnerthaler G, Tinchon C, Petzer A, et al
    Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
    Breast Cancer Res. 2021;23:112.
    PubMed     Abstract available


  310. GOLDBERG M, D'Aloisio AA, O'Brien KM, Zhao S, et al
    Early-life exposures and age at thelarche in the Sister Study cohort.
    Breast Cancer Res. 2021;23:111.
    PubMed     Abstract available


    November 2021
  311. VIROSTKO J, Sorace AG, Slavkova KP, Kazerouni AS, et al
    Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting.
    Breast Cancer Res. 2021;23:110.
    PubMed     Abstract available


  312. BOUCHERON P, Anele A, Zietsman A, Galukande M, et al
    Self-reported arm and shoulder problems in breast cancer survivors in Sub-Saharan Africa: the African Breast Cancer-Disparities in Outcomes cohort study.
    Breast Cancer Res. 2021;23:109.
    PubMed     Abstract available


  313. LABRECHE C, Cook DP, Abou-Hamad J, Pascoal J, et al
    Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFbeta/PI3K/AKT pathways.
    Breast Cancer Res. 2021;23:107.
    PubMed     Abstract available


  314. BARBER LE, Zirpoli GR, Cozier YC, Rosenberg L, et al
    Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women.
    Breast Cancer Res. 2021;23:108.
    PubMed     Abstract available


  315. LIU FC, Veierod MB, Kjaerheim K, Robsahm TE, et al
    Excess risk of male breast cancer in the Norwegian Offshore Petroleum Workers (NOPW) cohort: a possible link to extreme night shift work?
    Breast Cancer Res. 2021;23:106.
    PubMed    


  316. BODELON C, Mullooly M, Pfeiffer RM, Fan S, et al
    Mammary collagen architecture and its association with mammographic density and lesion severity among women undergoing image-guided breast biopsy.
    Breast Cancer Res. 2021;23:105.
    PubMed     Abstract available


  317. JESSER EA, Brady NJ, Huggins DN, Witschen PM, et al
    STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment.
    Breast Cancer Res. 2021;23:104.
    PubMed     Abstract available


  318. HANAMURA T, Christenson JL, O'Neill KI, Rosas E, et al
    Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
    Breast Cancer Res. 2021;23:102.
    PubMed     Abstract available


  319. COLLIN LJ, Maliniak ML, Cronin-Fenton DP, Ahern TP, et al
    Hypoxia-inducible factor-1alpha expression and breast cancer recurrence in a Danish population-based case control study.
    Breast Cancer Res. 2021;23:103.
    PubMed     Abstract available


    October 2021
  320. ROPRI AS, DeVaux RS, Eng J, Chittur SV, et al
    Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Breast Cancer Res. 2021;23:101.
    PubMed     Abstract available


  321. SCHERER SD, Riggio AI, Haroun F, DeRose YS, et al
    An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
    Breast Cancer Res. 2021;23:100.
    PubMed     Abstract available


  322. SAKAGUCHI A, Horimoto Y, Onagi H, Ikarashi D, et al
    Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res. 2021;23:99.
    PubMed     Abstract available


  323. FUH KF, Shepherd RD, Withell JS, Kooistra BK, et al
    Fluid flow exposure promotes epithelial-to-mesenchymal transition and adhesion of breast cancer cells to endothelial cells.
    Breast Cancer Res. 2021;23:97.
    PubMed     Abstract available


  324. CHEN X, Chen DG, Zhao Z, Balko JM, et al
    Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms.
    Breast Cancer Res. 2021;23:96.
    PubMed     Abstract available


  325. HAZLETT J, Niemi V, Aiderus A, Powell K, et al
    Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer.
    Breast Cancer Res. 2021;23:95.
    PubMed     Abstract available


    September 2021
  326. LIOU L, Kaptoge S, Dennis J, Shah M, et al
    Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study.
    Breast Cancer Res. 2021;23:94.
    PubMed     Abstract available


  327. LEOCE NM, Jin Z, Kehm RD, Roh JM, et al
    Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer.
    Breast Cancer Res. 2021;23:91.
    PubMed     Abstract available


  328. IONKINA AA, Balderrama-Gutierrez G, Ibanez KJ, Phan SHD, et al
    Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer.
    Breast Cancer Res. 2021;23:93.
    PubMed     Abstract available


  329. ZARE A, Postovit LM, Githaka JM
    Robust inflammatory breast cancer gene signature using nonparametric random forest analysis.
    Breast Cancer Res. 2021;23:92.
    PubMed     Abstract available


  330. IBRAHIM AM, Bilsland A, Rickelt S, Morris JS, et al
    A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.
    Breast Cancer Res. 2021;23:90.
    PubMed     Abstract available


  331. YANG L, Wang B, Jiao X, Zhou C, et al
    TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
    Breast Cancer Res. 2021;23:89.
    PubMed     Abstract available


    July 2021
  332. HIS M, Lajous M, Gomez-Flores-Ramos L, Monge A, et al
    Biomarkers of mammographic density in premenopausal women.
    Breast Cancer Res. 2021;23:75.
    PubMed     Abstract available


  333. LU P, Foley J, Zhu C, McNamara K, et al
    Transcriptome and genome evolution during HER2-amplified breast neoplasia.
    Breast Cancer Res. 2021;23:73.
    PubMed     Abstract available


  334. GARZIA NA, Cushing-Haugen K, Kensler TW, Tamimi RM, et al
    Adolescent and early adulthood inflammation-associated dietary patterns in relation to premenopausal mammographic density.
    Breast Cancer Res. 2021;23:71.
    PubMed     Abstract available


    June 2021
  335. RUTH JR, Pant DK, Pan TC, Seidel HE, et al
    Cellular dormancy in minimal residual disease following targeted therapy.
    Breast Cancer Res. 2021;23:63.
    PubMed     Abstract available


    May 2021
  336. SARRADIN V, Lusque A, Filleron T, Dalenc F, et al
    Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
    Breast Cancer Res. 2021;23:61.
    PubMed     Abstract available


  337. DE BOER LL, Kho E, Van de Vijver KK, Vranken Peeters MTFD, et al
    Optical tissue measurements of invasive carcinoma and ductal carcinoma in situ for surgical guidance.
    Breast Cancer Res. 2021;23:59.
    PubMed     Abstract available


  338. CONG L, Maishi N, Annan DA, Young MF, et al
    Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
    Breast Cancer Res. 2021;23:51.
    PubMed     Abstract available


    April 2021
  339. REIMERS LL, Goldberg M, Tehranifar P, Michels KB, et al
    Benign breast disease and changes in mammographic breast density.
    Breast Cancer Res. 2021;23:49.
    PubMed     Abstract available


  340. YANG HY, Tu CW, Chen CC, Lee CY, et al
    Sole adjuvant intraoperative breast radiotherapy in Taiwan: a single-center experience.
    Breast Cancer Res. 2021;23:43.
    PubMed     Abstract available


    February 2021
  341. SZUCS Z, Joseph J, Larkin TJ, Xie B, et al
    Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.
    Breast Cancer Res. 2021;23:25.
    PubMed     Abstract available


  342. TIAN J, Wang V, Wang N, Khadang B, et al
    Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
    Breast Cancer Res. 2021;23:23.
    PubMed     Abstract available


    January 2021
  343. ALTOE ML, Kalinsky K, Marone A, Kim HK, et al
    Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.
    Breast Cancer Res. 2021;23:16.
    PubMed     Abstract available


  344. BAI F, Liu S, Liu X, Hollern DP, et al
    PDGFRbeta is an essential therapeutic target for BRCA1-deficient mammary tumors.
    Breast Cancer Res. 2021;23:10.
    PubMed     Abstract available


  345. RIEDLINGER GM, Joshi S, Hirshfield KM, Barnard N, et al
    Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.
    Breast Cancer Res. 2021;23:7.
    PubMed     Abstract available


  346. MCCART REED AE, Kalinowski L, Simpson PT, Lakhani SR, et al
    Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
    Breast Cancer Res. 2021;23:6.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.